Abstract
Immunotherapy in colon cancer: approaching to the future
Highlights
Colon cancer is still a very common disease worldwide[1],[2] and the median survival in metastatic cases, not candidates to surgery, remains still less than 3 years[3].www.jumdjournal.netCidon
No differences at 7 years Longer follow up showed benefit in stage II only Reduction in recurrence rate of 61%vs . 87% in historical No differences in overall survival (OS) But significant improvement in colon compared to rectal cancer No benefits in progression-free survival (PFS)/OS
Immunotherapy is a breakthrough in cancer therapy and several agents are already approved to be used routinely in clinical practice, much remains to be done to be able to select the optimal population to achieve maximum responses
Summary
Colon cancer is still a very common disease worldwide[1], ( the use of screening strategies has reduced its incidence)[2] and the median survival in metastatic cases, not candidates to surgery, remains still less than 3 years[3]. Genomic instability in colon cancer places this tumour on the average group of mutation load[16], some cases have a high rate of mutations These are characterized by alterations in MMR genes leading to microsatellite instability high (MSI-H) which is present in only some of colon neoplasias as mentioned above, and its incidence reduces with more advanced stages. Following the success in the treatment of other neoplasias, different trials have been carried out in cancers such as colon As already mentioned, those metastatic colon cancers showing MSI-H, are associated with a high mutational burden and immune cell invasion, making them ideal for immune checkpoint inhibitors [Table 1]. Atezolizumab Atezolizumab/cobimetinib Atezolizumab/cobimetinib combo vs. atezolizumab vx regorafenib epacadostat /azacitidine/ pembrolizumab Pexidartinib/durvalumab Pembrolizumab/cetuximab
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call